1. In 1982, China and Sweden signed a Huarui Pharmaceutical contract.

2. In 1983, the foundation stone of Huarui Pharmaceutical Wuxi Factory was laid.

3. In February 1986, Ms. Zhou Qisi from Shanghai had her entire small intestine removed due to acute intestinal volvulus. With the selfless support of Huarui Pharmaceutical, she became the first person in China to rely entirely on parenteral nutrition. Cases of life-sustaining infusions.

4. On April 9, 1987, Huarui Pharmaceutical held a grand opening ceremony. Swedish Prime Minister Karlsson attended the opening ceremony and wrote an inscription: "An important moment for the relations between China and Sweden."

5. On April 8, 1992, Zhou Qisi gave birth to her daughter Cai Wei. Cai Wei became the first baby in the world to be conceived with parenteral complete nutritional infusion and was included in the Guinness Book of World Records.

6. In July 1992, Huarui Pharmaceutical won the second prize of the Science and Technology Progress Award of the Ministry of Health.

7. In 1995, the second phase project of Huarui Pharmaceutical Factory was laid.

8. In 1995, Huarui Pharmaceutical was rated as one of the top ten joint venture pharmaceutical companies by the State Administration of Medicine.

9. From 1994 to 1996, Huarui Pharmaceutical was rated as a national enterprise with excellent foreign investment.

10. In April 1998, Huarui Pharmaceutical passed the GMP certification of the Ministry of Health of China.

11. In June 1998, the second phase of the Huarui Pharmaceutical Factory with a total investment of nearly 300 million yuan was completed, marking the birth of a large-scale infusion production line in the Chinese pharmaceutical industry that has reached the world's advanced level in the early 21st century. , with an annual production capacity of 13 million bottles.

12. On August 3, 1999, the 30th board meeting of Huarui Pharmaceutical announced that Fresenius Kabi of Germany would become the company’s foreign shareholder.

13. In January 2000, the second phase of the factory passed China GMP certification.

14. On March 20, 2000, Huarui Pharmaceutical passed the ISO14001 certification organized by the China Environmental Management System Audit Center of the State Environmental Protection Administration and the British UKAS.

15. On June 16 and December 27, 2000, Huarui Pharmaceutical's large infusion and small needle production lines passed EU GMP certification respectively.

16. In August 2001, Huarui Pharmaceutical's enteral nutrition products Ruisu and Ruigao were launched on the market. Huarui became the only company in China that can provide enteral and parenteral nutrition products and services.

17. On September 12, 2001, Huarui Pharmaceutical received the first order of 500 bottles of 10% 500ML Intralipid to be shipped to Bangladesh, thus breaking the domestic zero export pattern of large infusion solutions. Record.

18. On October 11, 2001, Huarui Pharmaceutical signed the first large infusion order in history for exporting 650,000 bottles of 20% 250ML Intralipit and 20% 500ML to France in Europe.

19. In 2002, Huarui Pharmaceutical won the 2002 National "Double Excellence" Award for China's Foreign-Invested Enterprises.

20. On January 16, 2002, Huarui Pharmaceutical's 2002 annual marketing meeting was held in Bangkok, Thailand. This was the first time since the company's establishment that it had gone abroad to hold a large-scale internal meeting.

21. From March 11 to 15, 2002, Huarui Pharmaceutical underwent EU GMP review and obtained the GMP certification on May 17.

22. On April 4, 2002, the first batch of 38,400 units of Aquavita was airlifted from Shanghai to Stockholm, Sweden, marking the official launch of Aquavita’s export business and Huarui Pharmaceutical became The first domestic company to export freeze-dried powder for injection to the European market has achieved another historic breakthrough.

23. In July 2002, 30% Intralipit was rated as a national key new product.

24. In August 2002, Andame, Shuilevita, 30% Intralipit, Lefanming, and Lineng MCT were rated as high-tech products by Jiangsu Province.

25. In September 2002, the newly built oral emulsion production line passed China GMP certification.

26. In October 2002, 30% Intralipit won the third prize of Jiangsu Province Science and Technology Progress Award.

27. In November 2002, Huarui Pharmaceutical was rated as a high-tech enterprise in Jiangsu Province.

28. In April 2003, Huarui Pharmaceutical was rated as a key high-tech enterprise in the National Torch Plan.

29. In April 2003, the complete enteral nutrition emulsion project was included in the national Torch Plan project.

30. In April 2003, Ruineng and Ruisu were rated as national key new products.

31. On October 18, 2003, Huarui Pharmaceutical officially moved its management headquarters to the 18th floor of China Resources Building in Jianguomen, Beijing.

32. On December 8, 2003, Mr. Markus Schneider, the new executive president of the German Fresenius Group, visited Huarui’s Wuxi factory and Beijing headquarters.

33. In 2004, Huarui Pharmaceutical was rated as a green-level enterprise for environmental behavior information disclosure in Jiangsu Province.

34. In July 2004, Li Neng was rated as a national key new product.

35. In July 2004, Huarui Pharmaceutical launched the first three-chamber bag product in China

36. On September 17, 2004, Huarui Pharmaceutical passed the Jiangsu Province Biennial review of high-tech enterprises and technology-intensive and knowledge-intensive enterprises in Jiangsu Province.

37. On November 24-26, 2004, Huarui's large-volume injections and freeze-dried powder injections successfully passed the EU's biennial GMP certification review.

38. From December 18 to 20, 2004, the sterile drugs of Huarui Company successfully passed the GMP certification review organized by the State Food and Drug Administration.

39. On December 9-10, 2004, Huarui Company successfully passed the ISO14001 review organized by the Huaxia Certification Center.

40. On February 16, 2005, Lefanming (compound amino acid injection and its manufacturing method) was authorized by the national invention patent.

41. On March 1, 2005, the State Food and Drug Administration issued the "Notice on Carrying out the Pilot Work on Drug Parameter Release", and Huarui Company was listed as one of the two pilot companies in the country. , for a period of two years.

42. On March 7, 2005, Huarui Company obtained the "Medical Enterprise Business License", which marked that the company has the right to operate medical devices and its business areas have been further expanded.

43. In June 2005, the national sales volume of Kavin exceeded 10,000 bags.

44. In June 2005, Ruixian was recognized as a national key new product.

45. On December 28, 2005, the Ministry of Commerce of the People’s Republic of China approved Fresenius Kabi Co., Ltd. to transfer its 51% stake in Huarui Company to Fresenius Kabi (China) Investment Co., Ltd.

46. On May 6, 2006, Li Lanqing, former member of the Standing Committee of the Political Bureau of the Central Committee of the Communist Party of China and Executive Vice Premier of the State Council, inspected Huarui Company accompanied by provincial and municipal leaders. A symposium for leaders of Sino-foreign joint ventures in Suzhou, Wuzhou and Changzhou was held.

47. In June 2006, Huarui Company passed the review as a key high-tech enterprise under the National Torch Plan.

48. In November 2006, Huarui Company passed the review as a high-tech enterprise in Jiangsu Province.

49. In November 2006, Lefanming was recognized as a national key new product.

50. In 2006, Huarui Company was awarded the highest comprehensive award - "Take-off Award" by the Wuxi Municipal People's Government.

51. In December 2006, Huarui Company passed the Jiangsu Province technology-intensive knowledge-intensive enterprise review.

52. On December 20, 2006, Ruisu (fiber-free enteral nutritional preparation and its manufacturing method), Ruineng (enteral nutritional preparation for tumor patients and its manufacturing method) ) was authorized by the national invention patent.

53. On March 30-31, 2007, Huarui Company passed the parameter release on-site inspection of Jiangsu Provincial Food and Drug Administration.

54. On May 15, 2007, Huarui Company was rated as a "Foreign-invested Advanced Technology Enterprise" in Jiangsu Province.

55. On May 30, 2007, Bupleurum oil emulsion injection and its production method were authorized by the national invention patent.

56. On November 24, 2007, the 25th anniversary celebration of Huarui Pharmaceutical Co., Ltd. was held grandly at the Great Hall of the People in Wuxi.

57. In January 2008, it was recognized as a famous trademark of Jiangsu Province, and Intralipit was awarded the title of "Jiangsu Famous Brand Product".

58. On March 5, 2008, the Wuxi factory of Huarui Company successfully passed the ISO9001 certification inspection organized by the German TUV and received the certification.

59. On March 25, 2008, the Wuxi factory of Huarui Company successfully passed the ISO14001 audit organized by the German TUV and received the certification.

60. On September 26, 2008, Huarui Company laid the foundation stone for the third phase of the project.

61. On October 21, 2008, Huarui Company once again successfully passed the high-tech enterprise certification and obtained the certification jointly by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, the Jiangsu Provincial State Taxation Bureau, and the Jiangsu Provincial Local Taxation Bureau. High-tech enterprise certificate issued.

62. On December 12, 2008, "structured fat emulsion, amino acid and glucose injection composition packaged in three-cavity bags and its preparation method" was authorized by the national invention patent.

63. In December 2008, Huarui Company was awarded the title of "Excellent Enterprise for the 30th Anniversary of Wuxi Reform and Opening Up" by the Wuxi Municipal Party Committee and Wuxi Municipal People's Government. Being open to all rivers and bringing together talents is a vivid reflection of the talent philosophy of Huarui Pharmaceutical Co., Ltd. (hereinafter referred to as Huarui). Huarui attaches great importance to human resource development, adheres to the principle of "people-oriented, knows people and makes good use of them", and advocates the establishment of a learning organization. Huarui invests millions of yuan in special employee training every year, selects outstanding employees to study abroad, and successfully cultivates a large number of outstanding talents specializing in product research and development, production, quality management and marketing. Huarui also carries out the "Core Employee Plan" to select young employees with outstanding work and potential from various departments, increase the intensity and depth of training in a targeted manner, provide more development space and training opportunities, and achieve a reasonable allocation of training resources. , and also greatly enhanced the core competitiveness of the enterprise.

Huarui combines advanced production management technology with traditional humanistic spirit, advocates morality and encourages cooperation, forming a unique cultural charm and working atmosphere. Under the careful arrangements of the labor union and party organizations, employees have a rich and colorful spare time life, including photography associations, car enthusiasts associations, sports leagues, calligraphy and painting competitions, expansion training, and visits to revolutionary resorts... Every Huarui employee deeply loves his or her job. , love the like-minded partners around them, and also love Huarui Company, which is as warm as home and full of infinite vitality and vitality. They are willing to closely link their personal development with the name Huarui, and jointly look forward to the bright future of Chinese medical nutrition! In March 1998, the company donated 150,000 yuan to establish the "Huarui Hope Primary School" in Huangling County, Yan'an, and has since continued to organize employees to visit and donate to the teachers and students there.

In September 1998, the company donated medicines worth 2 million yuan to teachers and students in Hunan and Hubei where flood disasters occurred.

In 2000 and 2001, symphony concerts were held in Wuxi to support the development of local cultural undertakings.

In July 2000, the company donated 50,000 yuan to the Wuxi Volunteer Fund.

In January 2004, the Second Huarui Medical Science and Technology Award in Wuxi City awarded scientific and technological achievement awards and new technology introduction awards to 16 elites in the Wuxi medical field. The company invested 220,000 yuan.

The company has established scholarships for colleges and universities since 1994. Over the years, it has covered 15 colleges and universities, with a total scholarship of approximately 800,000 yuan. Huarui's foreign shareholder, Fresenius Kabi AG of Germany, is a wholly-owned subsidiary of the Fresenius Group. It is a leader in infusion therapy and clinical nutrition in Europe, with strong presence in its most important markets - Latin America and Asia-Pacific. The company ranks at the forefront and is one of the major suppliers in the US intravenous infusion pharmaceutical market.

Fika is committed to the treatment and care of critically ill patients and patients with chronic diseases both inside and outside the hospital.

Fresenius Kabi now has more than 20,000 employees around the world and a global network including 55 sales organizations and 55 production sites. In 2008, the company achieved sales of 2.495 billion euros and operating profit of 443 million euros.

China National Pharmaceutical Group Corporation, the main Chinese shareholder of Huarui Pharmaceutical Co., Ltd., was established on November 26, 1998. It is my country’s largest centrally managed pharmaceutical research, production and service trade company. The pharmaceutical enterprise group owns ten wholly-owned or holding subsidiaries and two listed companies, Sinopharm and Shenzhen Accord. In 2007, the sales revenue was 37.3 billion yuan, and the import and export volume was 770 million US dollars. In the 2006 ranking of China's large enterprises announced by the National Bureau of Statistics, China National Pharmaceutical Group ranked 99th, among 151 central enterprises, ranked 55th in sales revenue and 71st in profit.

China National Pharmaceutical Group Corporation takes "caring for life and protecting health" as its corporate philosophy and aims to create an industry-leading and internationally competitive pharmaceutical group. In China, we have production enterprises, scientific research and design institutes, medicinal material planting bases, and a marketing network located in major and medium-sized cities that basically covers the entire country. Since 1980, it has also cooperated with famous foreign multinational pharmaceutical companies and established 22 Sino-foreign joint venture pharmaceutical production enterprises, which has effectively promoted the improvement of my country's pharmaceutical production, operation and management levels.

China National Pharmaceutical Group Corporation has also established trade and cooperative relationships with thousands of companies in more than 100 countries and regions around the world, and has established offices in Hong Kong, Vietnam, Germany, the United States and relevant African countries and regions. There are subsidiaries or offices, and now we are gradually completing the transformation from mainly operating in the domestic market to transnational operations.

During the 2008 earthquake relief, China National Pharmaceutical Group responded quickly and went all out to complete the allocation of 300 million yuan in reserve medical supplies for earthquake relief, playing an important role at a critical moment.